TABLE 1.
Characteristics of patients with systolic heart failure due to ischemic cardiomyopathy
| Variable | The whole study group n = 53 (100%) |
TF+, FXIa+ n = 20 (37.7%) |
TF−, FXIa− n = 31 (58.5%) |
P |
|---|---|---|---|---|
| age, yrs | 61.5 ±8.3 | 57.9 ±7.1 | 63.7 ±8.5 | 0.01 |
| male sex, n (%) | 40 (75.5) | 13 (24.5) | 25 (47.2) | NS |
| BMI, kg/m2 | 28.8 ±3.7 | 28.7 ±3.4 | 28.6 ±3.9 | NS |
| myocardial infarction, n (%) | 18 (34.0) | 15 (28.3) | 1 (1.9) | <0.0001 |
| arterial hypertension, n (%) | 38 (71.7) | 11 (20.8) | 26 (49.1) | 0.02 |
| current smoking, n (%) | 17 (32.1) | 9 (17.0) | 7 (13.2) | NS |
| diabetes mellitus, n (%) | 11 (20.8) | 3 (5.7) | 7 (13.2) | NS |
| medication | ||||
| statins, n (%) | 44 (83.0) | 17 (32.1) | 27 (50.9) | NS |
| aspirin, n (%) | 46 (86.8) | 16 (30.2) | 28 (52.8) | NS |
| ACEI, n (%) | 35 (66.0) | 10 (18.9) | 23 (43.4) | NS |
| ARA, n (%) | 9 (17.0) | 3 (5.7) | 6 (11.3) | NS |
| β-blockers, n (%) | 30 (56.6) | 9 (17.0) | 19 (35.8) | NS |
| digoxin, n (%) | 7 (13.2) | 5 (9.4) | 2 (3.8) | NS |
| laboratory parameters | ||||
| TC, mM | 4.5 [4.0–5.0] | 4.5 [4.1–5.1] | 4.4 [3.8–5.0] | NS |
| LDL-C, mM | 2.7 [2.4–3.1] | 2.7 [2.3–3.3] | 2.7 [2.4–3.1] | NS |
| HDL-C, mM | 1.2 [1.0–1.3] | 1.2 [1.0–1.3] | 1.1 [1.0–1.3] | NS |
| triglycerides, mM | 1.5 [1.1–2.1] | 1.6 ±0.7 | 1.6 ±0.6 | NS |
| creatinine, μM | 96.6 ±28.3 | 94.0 [81.5–112.5] | 97 [78–120] | NS |
| hs-CRP, mg/l | 2.6 [1.6–3.8] | 2.6 [1.4–3.7] | 2.2 [1.6–4.1] | NS |
| glucose, mM | 5.3 [4.8–5.9] | 5.2 [4.8–5.6] | 5.3 [4.8–6.3] | NS |
| platelets, ×1000/μl | 226 [200–261] | 235 [210–286] | 220 [187–258] | NS |
| fibrinogen, g/l | 3.7 [3.0–4.8] | 3.4 [2.9–4.2] | 3.9 [3.1–4.9] | NS |
| PAI-1:Ag, ng/ml | 15.0 [11.4–20.7] | 17.3 [10.5–22.0] | 14.9 [11.9–20.7] | NS |
| tPA:Ag, ng/ml | 10.8 [9.2–13.2] | 11.0 [8.7–13.3] | 10.7 [9.6–12.6] | NS |
| F1+2, pM | 221.3 [185.4–297.4] | 300.7 [275.5–339.0] | 191.8 [171.2–221.1] | <0.0001 |
Values are mean ± SD or median [25–75%]
Abbreviations: ACEI – angiotensin-converting enzyme inhibitors, ARA – angiotensin II receptor subtype 1 antagonists, BMI – body mass index, FXIa – activated factor XI, FXIa+ – patients with detectable FXIa, FXIa− – patients with undetectable FXIa, F1+2 – prothrombin fragments 1+2, HDL-C – high-density lipoprotein cholesterol, hs-CRP – high-sensitivity C-reactive protein, LDL-C – low-density lipoprotein cholesterol, NS – nonsignificant (P >0.05), PAI-1:Ag – plasminogen activator inhibitor-1 antigen, SD – standard deviation, TC – total cholesterol, TF – tissue factor, TF+ – patients with detectable TF, TF− – patients with undetectable TF, tPA – tissue plasminogen activator